Sunesis Pharmaceuticals (SNSS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Affirms Sunesis (SNSS) at 'Neutral'; ASH Presentations May Help Clear Cloudy Outlook
November 11, 2014 9:12 AM ESTRoth Capital affirms its Neutral rating and $1.30 price target on Sunesis Pharma (Nasdaq: SNSS) following Q3 results. Early Monday, Sunesis reported Q3 loss of $0.25 per share, whle the firms was looking for a loss of just $0.07 per share.
Analyst Joseph Pantginis commented on the results: With the recent Phase III VALOR study not achieving its endpoint of OS, we are mindful of developments... More
